Prospective cohort study with active surveillance for fever in four dengue endemic countries in Latin America

American Journal of Tropical Medicine and Hygiene

Volumn 93, Issue 1, 2015, Pages 18-23

  Dayan, Gustavo ^a   Arredondo, Jose L ^b   Carrasquilla, Gabriel ^c   Deseda, Carmen C ^d   Dietze, Reynaldo ^e   Luz, Kleber ^f   Costa, Maria Selma N ^g   Cunha, Rivaldo V ^h   Rey, Luis C ⁱ   Morales, Javier ^j   Reynales, Humberto ^k   Miranda, Maria ^l   Zambrano, Betzana ^m   Rivas, Enrique ⁿ   Garbes, Pedro ^o   Noriega, Fernando ^a  

^a SANOFI PASTEUR   (France)

^b INSTITUTO NACIONAL DE PEDIATRÍA   (Mexico)

^c HOSPITAL UNIVERSITARIO FUNDACIÓN SANTA FE DE BOGOTÁ   (Colombia)

^d Caribbean Travel Medicine Clinic   (Puerto Rico)

^e FEDERAL UNIVERSITY OF ESPÍRITO SANTO   (Brazil)

^f FEDERAL UNIVERSITY OF RIO GRANDE DO NORTE   (Brazil)

^g FEDERAL UNIVERSITY OF GOIÁS   (Brazil)

^h FEDERAL UNIVERSITY OF MATO GROSSO DO SUL   (Brazil)

ⁱ FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

^j Clinical Research Puerto Rico Inc   (Puerto Rico)

^k Centro de Atencion e Investigación Médica   (Colombia)

^l City Business Piso 9   (Colombia)

^m Edif Corporate El Plata   (Uruguay)

ⁿ Clinical Research and Development ^*  (Mexico)

^o Research and Development   (Brazil)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DENGUE VACCINE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M; NONSTRUCTURAL PROTEIN 1; VIRUS ANTIBODY; VIRUS ANTIGEN;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; COHORT ANALYSIS; CONTROLLED STUDY; CONVALESCENCE; DENGUE; DISEASE SURVEILLANCE; DRUG EFFICACY; ENDEMIC DISEASE; FEVER; FOLLOW UP; HIGH RISK POPULATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; PERSONAL EXPERIENCE; PHASE 3 CLINICAL TRIAL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SCHOOL CHILD; SEROPREVALENCE; SOUTH AND CENTRAL AMERICA; VIROLOGY; BLOOD; BRAZIL; COLOMBIA; DENGUE VIRUS; EPIDEMIOLOGICAL MONITORING; FEMALE; IMMUNOLOGY; MALE; MEXICO; PUERTO RICO;

ADOLESCENT; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; BRAZIL; CHILD; COHORT STUDIES; COLOMBIA; DENGUE; DENGUE VIRUS; ENDEMIC DISEASES; EPIDEMIOLOGICAL MONITORING; FEMALE; FEVER; HUMANS; INCIDENCE; MALE; MEXICO; PROSPECTIVE STUDIES; PUERTO RICO;

EID: 84936991949     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.13-0663     Document Type: Article

References (39)

1. San Martín JL, Brathwaite O, Zambrano B, Solórzano JO, Bouckenooghe A, Dayan GH, Guzmán MG, 2010. The epidemiology of dengue in the Americas over the last three decades: a worrisome reality. Am J Trop Med Hyg 82: 128-135.
2. Padilla JC, Rojas DP, Sáenz-Gómez R, 2012. Dengue en Colombia: Epidemiología de la Reemergencia a la Hiperendemia. Bogotá, Colombia: Guías de Impresión LTDA.
3. Sequeira M, Espinoza H, Amador JJ, Domingo G, Quintanilla M, de los Santos T, 2011. Dengue in Nicaragua. Available at: http://www.path.org/publications/files/TS-nicaragua-dengue-rpt.pdf. Accessed October 11, 2013.
4. Teixeira MG, Costa NM, Coelho G, Barreto ML, 2008. Recent shift in age pattern of dengue hemorrhagic fever, Brazil. Emerg Infect Dis 14: 1663.
5. Shepard DS, Coudeville L, Halasa YA, Zambrano B, Dayan GH, 2011. Economic impact of dengue illness in the Americas. Am J Trop Med Hyg 84: 200-207.
6. Hurtado-Díaz M, Riojas-Rodríguez H, Rothenberg SJ, Gomez-Dantés H, Cifuentes E, 2007. Short communication: impact of climate variability on the incidence of dengue in Mexico. Trop Med Int Health 12: 1327-1337.
7. Barclay E, 2008. Is climate change affecting dengue in the Americas? Lancet 371: 973-974.
8. Pan American Health Organization (PAHO), Dengue. 2013. Available at: http://new.paho.org/hq/index.php?option=com-content&task=view&id=264&Itemid=363&lang=es. Accessed March 20, 2014.
9. Coller BA, Clemens DE, 2011. Dengue vaccines: progress and challenges. Curr Opin Immunol 23: 391-398.
10. Guirakhoo F, Weltzin R, Chambers TJ, Zhang ZX, Soike K, Ratterree M, Arroyo J, Georgakopoulos K, Catalan J, Monath TP, 2000. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates. J Virol 74: 5477-5485.
11. Guirakhoo F, Arroyo J, Pugachev KV, Miller C, Zhang ZX, Weltzin R, Georgakopoulos K, Catalan J, Ocran S, Soike K, Ratterree M, Monath TP, 2001. Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine. J Virol 75: 7290-7304.
12. Capeding RZ, Luna IA, Bomasang E, Lupisan S, Lang J, Forrat R, Wartel A, Crevat D, 2011. Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the Philippines. Vaccine 29: 3863-3872.
13. Guirakhoo F, Kitchener S, Morrison D, Forrat R, McCarthy K, Nichols R, Yoksan S, Duan X, Ermak TH, Kanesa-Thasan N, Bedford P, Lang J, Quentin-Millet MJ, Monath TP, 2006. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Hum Vaccin 2: 60-67.
14. Morrison D, Legg TJ, Billings CW, Forrat R, Yoksan S, Lang J, 2010. A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults. J Infect Dis 201: 370-377.
15. Qiao M, Shaw D, Forrat R, Wartel-Tram A, Lang J, 2011. Priming effect of dengue and yellow fever vaccination on the immunogenicity, infectivity, and safety of a tetravalent dengue vaccine in humans. Am J Trop Med Hyg 85: 724-731.
16. Lanata CF, Andrade T, Gil AI, Terrones C, Valladolid O, Zambrano B, Saville M, Crevat D, 2012. Immunogenicity and safety of tetravalent dengue vaccine in 2-11 year-olds previously vaccinated against yellow fever: randomized, controlled, phase II study in Piura, Peru. Vaccine 30: 5935-5941.
17. Poo J, Galan F, Forrat R, Zambrano B, Lang J, Dayan GH, 2011. Live-attenuated tetravalent dengue vaccine in dengue-naive children, adolescents, and adults in Mexico City: randomized controlled phase 1 trial of safety and immunogenicity. Pediatr Infect Dis J 30: e9-e17.
18. Sin LY, Wilder-Smith A, Archuleta S, Shek L, Chong CY, Nam LH, Yong LC, Oh ML, Bouckenooghe A, Crevat D, Wartel A, 2012. Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2-45 y: phase II randomized controlled trial in Singapore. Hum Vaccin Immunother 8: 1259-1271.
19. Villar LA, Rivera-Medina DM, Arredondo-García JL, Boaz M, Starr-Spires L, Thakur M, Zambrano B, Miranda MC, Rivas E, Dayan GH, 2013. Safety and immunogenicity of a recombinant tetravalent dengue vaccine in 9-16-year-olds: a randomized, controlled, phase II trial in Latin America. Pediatr Infect Dis J 32: 1102-1109.
20. Sabchareon A, Wallace D, Sirivichayakul C, Limkittikul K, Chanthavanich P, Suvannadabba S, Jiwariyavej V, Dulyachai W, Pengsaa K, Wartel TA, Moureau A, Saville M, Bouckenooghe A, Viviani S, Tornieporth NG, Lang J, 2012. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomized, controlled phase 2b trial. Lancet 380: 1559-1567.
21. Clopper C, Pearson ES, 1934. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 26: 404-413.
22. Rothman KJ, Greenland S, 1998. Modern Epidemiology. Second edition. New York, NY: Lippincott-Raven.
23. World Health Organization, 1997. Dengue Hemorrhagic Fever: Diagnosis, Treatment, Prevention and Control. Second edition. Geneva: World Health Organization.
24. Blacksell SD, Newton PN, Bell D, Kelley J, Mammen MP, Vaughn DW, Wuthiekanun V, Sungkakum A, Nisalak A, Day NP, 2006. The comparative accuracy of 8 rapid immunochromatographic assays for the diagnostic of acute dengue virus infection. Clin Infect Dis 42: 1127-1134.
25. Hunsperger EA, Yoksan S, Buchy P, Nguyen VC, Sekaran SD, Enria DA, Pelegrino JL, Vazquez S, Artsob H, Drebot M, Gubler DJ, Halstead SB, Guzman MG, Margolis HS, Nathanson CM, Rizzo Lic NR, Bessoff KE, Kliks S, Peeling RW, 2009. Evaluation of commercially available anti-dengue virus immunoglobulin M tests. Emerg Infect Dis 15: 436-440.
26. Vaughn DW, Nisalak A, Solomon T, Kalayanarooj S, Dung NM, Kneen R, Cuzzubbo A, Devina PL, 1999. Rapid serologic diagnosis of dengue virus infection using a commercial capture ELISA that distinguishes primary and secondary infections. Am J Trop Med Hyg 60: 693-698.
27. Guzman MG, Jaenisch T, Gaczkowski R, Hang VT, Sekaran SD, Kroeger A, Vazques S, Ruiz D, Martinez E, Mercado JC, Balmaseda A, Harris E, Dimano E, Leano PSA, Yoksan S, Villegas E, Benduzu H, Villalobos I, Farrar J, Simmons CP, 2010. Multi-country evaluation of the sensitivity and specificity of two commercially-available NS1 ELISA assays for dengue diagnosis. PLoS Negl Trop Dis 4: e811.
28. Hang VT, Nguyet NM, Trung DT, Tricou V, Yoksan S, Dung NM, Ngoc TV, Hien TT, Farrar J, Wills B, Simmons CP, 2009. Diagnostic accuracy of NS1ELISA and lateral flow rapid tests for dengue sensitivity, specificity and relationship to viraemia and antibody responses. PLoS Negl Trop Dis 3: e360.
29. Lapphra K, Sangcharaswichai A, Chokephaibulkit K, Tiengrim S, Piriyakarnsakul W, Chakorn T, Yoksan S, Wattanamongkolsil L, Thamlikitkul V, 2008. Evaluation of an NS1 antigen detection for diagnosis of acute dengue infection in patients with acute febrile illness. Diagn Microbiol Infect Dis 60: 387-391.
30. Felix AC, Romano CM, Centrone Cde C, Rodrigues CL, Villas-Boas L, Araujo ES, de Matos AM, Carvalho KI, Turchi Martelli CM, Kallas EG, Pannuti CS, Levi JE, 2012. Low sensitivity of NS1 protein tests evidenced during a dengue type 2 virus outbreak in Santos, Brazil, in 2010. Clin Vaccine Immunol 19: 1972-1976.
31. Gubler D, 2002. How effectively is epidemiological surveillance used for dengue programme planning and epidemic response? Dengue Bull 26: 96-106.
32. Suaya JA, Shepard DS, Beatty M, Farrar J, 2010. Disease burden of dengue fever and dengue hemorrhagic fever. Preedy VR, Watson RR, eds. Handbook of Disease Burdens and Quality of Life Measures. New York, NY: Springer, 1263-1279.
33. Luz PM, Grinsztejn B, Galvani AP, 2009. Disability adjusted life years lost to dengue in Brazil. Trop Med Int Health 14: 237-246.
34. Armien B, Suaya JA, Quiroz E, Sah BK, Bayard V, Marchena L, Campos C, Shepard DS, 2008. Clinical characteristics and national economic cost of the 2005 dengue epidemic in Panama. Am J Trop Med Hyg 79: 364-371.
35. Meltzer MI, Rigau-Perez JG, Clark GG, Reiter P, Gubler DJ, 1998. Using disability-adjusted life years to assess the economic impact of dengue in Puerto Rico: 1984-1994. Am J Trop Med Hyg 59: 265-271.
36. Camacho T, de la Hoz F, Cardenas V, Sanchez C, de Calderon L, Perez L, Bermudez A, 2004. Incomplete surveillance of a dengue-2 epidemic in Ibague, Colombia, 1995-1997. Biomedica 24: 174-182.
37. Standish K, Kuan G, Aviles W, Balmaseda A, Harris E, 2010. High dengue case capture rate in four years of a cohort study in Nicaragua compared to national surveillance data. PLoS Negl Trop Dis 4: e633.
38. Ramos MM, Argüello DF, Luxemburger C, Quiñones L, Muñoz JL, Beatty M, Lang J, Tomashek KM, 2008. Epidemiological and clinical observations on patients with dengue in Puerto Rico: results from the first year of enhanced surveillance-June 2005-May 2006. Am J Trop Med Hyg 79: 123-127.
39. Restrepo AC, Baker P, Clements AC, 2014. National spatial and temporal patterns of notified dengue cases, Colombia 2007-2010. Trop Med Int Health 19: 863-871.